Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2020: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2018: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
Outline of Final Research Achievements |
Advanced/metastatic renal cell carcinoma (RCC) is a disease with a poor prognosis without useful biomarkers. In this study, we aimed to establish a liquid biopsy-based biomarkers using comprehensive glycosylation of serum and cell free DNA (cfDNA). We analyzed 100 samples to select the candidate molecules (glycans and genes). We developed diagnostic N-glycan score to detect RCC. We found diagnostic N-glycan score were useful to detect RCC with a high accuracy. We found the G250 gene, which is specific for RCC, was not useful. Further study is necessary to examine whether biomarkers using glycans correlate with images in the future.
|